Stock Market News3 days Can Gilead Sciences Sustain Its Growth Momentum in 2025? Zacks
GILD has performed well in the past six months, with new drug approvals, positive data readouts and strong quarterly results. While the fundamentals look solid, we advise investors to remain on the sidelines at current levels.
X